Skip to content

Botox and Botox Cosmetic

Botox and Botox Cosmetic are AbbVie’s brands of onabotulinumtoxinA, a botulinum toxin type A medicine. AbbVie acquired Allergan and the Botox franchise in 2020; AbbVie / Allergan explains the ownership and company history (AbbVie acquisition announcement 🔗). In the United States, Botox has therapeutic approvals, while Botox Cosmetic has aesthetic approvals. Their shared ingredient does not make their labeled uses identical (Botox prescribing information 🔗; Botox Cosmetic prescribing information 🔗).

Vistabel and Vistabex are European aesthetic brand names within the Botox product family. Their regional names and European product information retain their own national approval context (FDA clinical review of Botox, product background 🔗).

The FDA-approved uses below separate medical indications from cosmetic treatment areas; approval milestones distinguish the original therapeutic approval from later expansions. The broader FDA-approved botulinum toxin list and U.S. timeline includes other brands.

Botox belongs to the botulinum toxin type A group, but its units, indications, preparation, and safety language are product-specific. Botox should not be treated as a default conversion standard for Dysport, Xeomin, Jeuveau, Daxxify, Letybo, Myobloc, or any other toxin product.

AbbVie Inc. is the manufacturer named in the U.S. prescribing information for both Botox and Botox Cosmetic. Both labels give a North Chicago, Illinois address and identify BOTOX as a trademark of Allergan, Inc., an AbbVie company (Botox prescribing information — AbbVie 🔗; Botox Cosmetic prescribing information — AbbVie 🔗).

Physical production location is a separate fact. The 2024 environmental report for the Westport, County Mayo, Ireland site records Botox manufacture and identifies the company as AbbVie trading as Allergan Pharmaceuticals Ireland Unlimited Company. The U.S. label’s company address alone does not establish a U.S. production location (Westport Annual Environmental Report — Irish EPA 🔗).

Allergan Aesthetics is AbbVie’s aesthetics business, including Botox Cosmetic. Its business name should not be used to describe the entire therapeutic Botox franchise or replace the manufacturer named in a product label (About Allergan Aesthetics 🔗; AbbVie acquisition announcement 🔗).

FieldReference point
BrandBotox / Botox Cosmetic
Nonproprietary nameOnabotulinumtoxinA
Toxin typeBotulinum toxin type A
U.S. label manufacturerAbbVie Inc. (Botox prescribing information 🔗)
Parent companyAbbVie, following its 2020 acquisition of Allergan 🔗
Aesthetics businessAllergan Aesthetics, an AbbVie company; includes Botox Cosmetic (About Allergan Aesthetics 🔗)
Brand heritageAllergan; company history and manufacturing relationships

Vistabel is a regional aesthetic name associated with Botox / Botox Cosmetic. Vistabex is the name used in Italy. The Spanish patient leaflet lists Vistabel across numerous European Economic Area (EEA) countries, including France, Germany, Ireland, and Spain, and Vistabex in Italy. That authorisation-name list does not establish actual commercial availability in every listed country (Vistabel patient leaflet, section 6 — AEMPS 🔗).

The names connect the product family; approved uses remain tied to the exact product and country. Spain has separate records for Botox and Vistabel, both naming AbbVie Spain, S.L.U. as marketing authorisation holder. The EU approval overview links those national records and distinguishes national authorisations from centralised EU approval (Botox SmPC, section 7 — AEMPS 🔗; Vistabel SmPC, section 7 — AEMPS 🔗).

The Spanish Vistabel Summary of Product Characteristics (SmPC) covers temporary improvement in the appearance of moderate to severe facial lines in adults when their severity has an important psychological impact. Section 4.1 identifies the following areas, individually and/or in the combinations described in the product information (Vistabel SmPC, sections 4.1–4.2 — AEMPS 🔗):

Approved areaExpression specified in the Spanish label
Glabellar lines — vertical lines between the eyebrowsMaximum frown.
Lateral canthal lines / crow’s feetMaximum smile.
Forehead linesMaximum eyebrow elevation.

Section 4.1 specifies adults without an under-65 cutoff; section 4.2 notes limited phase III data in people older than 65. These are distinct statements about indication scope and evidence, rather than a universal age rule for the Botox family (Vistabel SmPC, sections 4.1–4.2 — AEMPS 🔗).

The EU indication matrix keeps Spanish Vistabel and therapeutic Botox entries separate. The U.S. Botox Cosmetic indications below do not establish Spanish Vistabel approval, and the Spanish label does not establish approved uses throughout Europe.

Botox has separate therapeutic and aesthetic label contexts in the United States. Botox and Botox Cosmetic share the onabotulinumtoxinA product identity, but the meaning of a claim depends on the specific label, indication, dose language, and patient population being discussed.

Neither label makes Botox a generic synonym for botulinum toxin treatment. The approved uses below summarize the indications and key population limits; full prescribing information also defines contraindications, warnings, preparation, and dosing.

The Botox therapeutic prescribing information, sections 1.1–1.7 🔗, defines these medical indications:

Approved usePatient population and key limits
Overactive bladderAdults with urge urinary incontinence, urgency, and frequency after inadequate response or intolerance to anticholinergic medication.
Urinary incontinence from neurologic detrusor overactivityAdults after inadequate response or intolerance to anticholinergic medication.
Pediatric neurogenic detrusor overactivityAge 5 and older after inadequate response or intolerance to anticholinergic medication.
Headache prevention in chronic migraineAdults with at least 15 headache days per month, lasting at least 4 hours a day.
SpasticityAge 2 and older; upper- and lower-limb dosing is specified separately.
Cervical dystoniaAdults; reduction of abnormal head position and associated neck pain.
Severe primary axillary hyperhidrosisAdults whose underarm sweating is inadequately managed by topical agents.
Blepharospasm associated with dystoniaAge 12 and older.
StrabismusAge 12 and older.

Detrusor overactivity refers to involuntary bladder-muscle contractions. The label distinguishes these bladder indications and their eligible populations. It also states that safety and effectiveness have not been established for episodic migraine prevention or sweating in body areas other than the underarms (Botox prescribing information — AbbVie, indications and limitations 🔗).

The Botox Cosmetic prescribing information on DailyMed, section 1 🔗, covers temporary improvement in the appearance of these moderate to severe features in adults:

Approved aesthetic useAssociated muscle activity specified in the label
Glabellar lines — frown lines between the eyebrowsCorrugator and/or procerus muscles.
Lateral canthal lines / crow’s feetOrbicularis oculi muscle.
Forehead linesFrontalis muscle.
Platysma bands — vertical neck bandsPlatysma muscle.

The shared ingredient does not extend this label to every cosmetic use of botulinum toxin. Forehead-line dosing in the prescribing information includes simultaneous treatment of glabellar lines; the treatment areas are not independent dosing instructions.

Both labels carry a boxed warning about effects spreading beyond the injection area, including potentially life-threatening swallowing or breathing difficulties. Their potency units are product-specific and cannot be converted to those of another botulinum toxin preparation (Botox prescribing information 🔗; Botox Cosmetic prescribing information 🔗). An approved treatment area does not establish suitability for an individual patient.

The U.S. indication matrix compares product-specific label scopes across brands. A use outside the relevant approved label is off-label; clinical use or acceptance of an application for FDA review does not establish approval.

Botox and Botox Cosmetic FDA Approval History

Section titled “Botox and Botox Cosmetic FDA Approval History”

1989 marks the initial U.S. therapeutic approval; April 12, 2002 marks the glabellar-line approval marketed as Botox Cosmetic. The FDA label’s initial-approval year should not be read as the cosmetic indication’s approval date (FDA orphan-drug record 🔗; FDA 2002 approval letter 🔗).

DateProduct and selected approval milestoneFDA source
December 1989Original therapeutic approval: the orphan-drug record lists December 29 for strabismus and December 30 for blepharospasm.FDA orphan-drug record 🔗
April 12, 2002Botox Cosmetic: glabellar lines; the original approval specified adults under 65.Approval letter 🔗
October 15, 2010Botox: headache prevention in adults with chronic migraine.Approval letter 🔗
September 11, 2013Botox Cosmetic: lateral canthal lines / crow’s feet in adults.Approval letter 🔗
October 2017Botox Cosmetic: forehead lines in adults; the historical label identifies the change by month.FDA 2017 label 🔗
October 2024Botox Cosmetic: platysma bands in adults; the FDA label identifies the major-change month.FDA 2024 label 🔗

These are selected milestones, not every therapeutic expansion or label revision. Historical approval language can differ from current prescribing information; the original 2002 age limit is not the current Botox Cosmetic adult-indication wording. Cross-brand milestones remain in the U.S. FDA approval timeline, and application-review stages are tracked separately under U.S. regulatory status.

Botox is a category reference brand because it connects early regulatory history, broad clinical recognition, and strong consumer awareness. That visibility can make cross-brand discussion easier for readers, but it can also blur important distinctions.

Comparisons with Dysport, Xeomin, Jeuveau, Daxxify, or Letybo should be framed around product identity, label context, evidence, and local regulation. A headline unit number, patient anecdote, or brand familiarity cannot establish equivalence.

AbbVie / Allergan supplies the company context behind Botox. Justinus Kerner and Émile van Ermengem anchor the pre-product botulism and microbiology history. Edward J. Schantz connects the toxin-science and purification background with medical use; his review with Eric A. Johnson describes those properties and their therapeutic application (Schantz and Johnson, Microbiological Reviews, 1992 🔗). Alan B. Scott anchors the therapeutic Oculinum / Botox origin story, and Richard Clark, Jean Carruthers, and Alastair Carruthers anchor the early aesthetic and Botox Cosmetic glabellar-line adoption pathway.

Joseph Jankovic, M.D. connects early controlled dystonia trials with the wider neurological adoption of therapeutic botulinum toxin. Mitchell Brin, M.D. connects clinical botulinum toxin research with later Allergan and AbbVie development, licensure, and neurotoxin-franchise science. David E. I. Pyott explains the Allergan executive period in which Botox Cosmetic gained its U.S. glabellar-line approval and the Botox franchise became a major global commercial reference point.

Botulinum toxin explains the broader medicine family, while type A vs type B separates Botox from type B products such as Myobloc / Neurobloc.

1. A Botox Cosmetic label states 'Initial U.S. Approval: 1989.' Which evidence establishes when its forehead-line indication was approved?
2. A reader finds a U.S. Botox Cosmetic indication and wants to know whether it is approved for Vistabel in Spain. Which evidence answers that question?
3. Another botulinum toxin product is described with a higher unit count than Botox. What can be concluded from those numbers alone?